2.94

2.80% 0.08

Aadi Bioscience Inc (AADI)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AADI? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.86

Offen:

$2.8

24-Stunden-Volumen:

248.29K

Relative Volume:

0.95

Marktkapitalisierung:

$71.23M

Einnahmen:

$23.26M

Nettoeinkommen (Verlust:

$-63.41M

KGV:

-1.2049

EPS:

-2.44

Netto-Cashflow:

$-64.56M

1W Leistung:

+23.01%

1M Leistung:

+27.83%

6M Leistung:

+68.00%

1J Leistung:

+49.24%

1-Tages-Spanne:

$2.7519

$3.04

1-Wochen-Bereich:

$2.07

$3.60

52-Wochen-Spanne:

$1.21

$3.60

Aadi Bioscience Inc Stock (AADI) Company Profile

Firmenname

Aadi Bioscience Inc

Sektor

Healthcare (1178)

Branche

Biotechnology (680)

Telefon

424-473-8055

Adresse

17383 SUNSET AVENUE, PACIFIC PALISADES

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-12-06

Neueste SEC-Einreichungen

AADI's Discussions on Twitter

Vergleichen Sie AADI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AADI Aadi Bioscience Inc	2.94	71.23M	23.26M	-63.41M	-64.56M	-2.36
VRTX Vertex Pharmaceuticals Inc	407.57	105.01B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	714.47	78.17B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	629.39	37.48B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	243.25	30.94B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.13	27.15B	3.30B	-501.07M	1.03B	-2.1146

Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-27	Herabstufung	Piper Sandler	Overweight → Neutral
2024-08-21	Herabstufung	Jefferies	Buy → Hold
2024-08-21	Herabstufung	TD Cowen	Buy → Hold
2023-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-01-11	Eingeleitet	Jefferies	Buy
2021-10-01	Eingeleitet	Cowen	Outperform
2021-09-14	Eingeleitet	Ladenburg Thalmann	Buy
2021-09-08	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Aadi Bioscience Inc Aktie (AADI) Neueste Nachrichten

Dec 23, 2024

Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World

Dec 23, 2024

Dec 22, 2024

Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini

Dec 20, 2024

Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Scrip

Dec 20, 2024

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga

Dec 20, 2024

Aadi Bioscience stock soars on licensing and sale deals - Investing.com India

Dec 20, 2024

Dec 19, 2024

Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com

Dec 19, 2024

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance

Dec 19, 2024

Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com

Dec 19, 2024

Clinical Trials News Live Feed - StockTitan

Dec 19, 2024

Dec 15, 2024

Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat

Dec 15, 2024

Dec 11, 2024

AADI Enlists NY Court To Enforce Cancer Drug Award - Law360

Dec 11, 2024

Dec 03, 2024

Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 03, 2024

Dec 02, 2024

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 8.8% - MarketBeat

Dec 02, 2024

Nov 26, 2024

GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World

Nov 26, 2024

Nov 19, 2024